Hexarelin vs Ipamorelin: GH, Selectivity & Human Evidence

At a Glance: Side-by-Side Comparison

Mechanism: Selectivity Needs an Evidence Level

Ipamorelin is a pentapeptide whose original experiments in rat pituitary cells, rats and swine demonstrated a GHRP-like receptor mechanism. In swine, its ACTH and cortisol responses resembled those after GHRH more closely than those after GHRP-2 or GHRP-6. This is a favorable preclinical selectivity finding, not a matched human comparison with hexarelin. 1998 ipamorelin animal pharmacology study

That experiment does not establish a separate GHIP pathway that suppresses cortisol and prolactin in people, or a GHS-R1b explanation for safer chronic use. Receptor activity, hormone selectivity and clinical tolerability are different claims; demonstrating one does not establish all three.

GH Release: Correct the Units Before Comparing Peaks

Human ipamorelin research demonstrates GH stimulation. A dose-escalation study used five 15-minute infusion exposures, with eight healthy men at each level. The investigators reported an approximately two-hour terminal peptide half-life and a GH peak at 0.67 hours, with substantial variability in the hormone response. Those are study-specific observations, not a subcutaneous injection schedule. 1999 human ipamorelin PK/PD study

The same report's modeled maximum GH production rate was 694 mIU/L/h. A production rate is not a blood concentration, and neither is equivalent to the IU amount in an HGH injection. The reviewed evidence does not support universal serum peaks of 20-50 IU/mL for hexarelin versus 10-30 IU/mL for ipamorelin. 1999 human ipamorelin PK/PD study

Comparing separate experiments also requires matching the population, route, exposure, sampling and assay. A larger GH response under one test condition does not by itself demonstrate greater muscle gain or a better long-term treatment.

Hormone Effects and Clinical Tolerability Are Different Outcomes

Acute human hexarelin data document effects beyond GH. In seven young adults, intravenous hexarelin, GHRP-2 and Tyr-Ala-hexarelin each stimulated prolactin, ACTH and cortisol. Ipamorelin was not tested in that experiment, so the result cannot quantify a head-to-head safety difference. 1999 acute human endocrine study

Ipamorelin's animal selectivity should not be rewritten as a promise of no human hormone effects. In the original swine experiment, none of the tested secretagogues changed prolactin, including the comparators. That particular finding cannot establish that ipamorelin uniquely avoids prolactin-related effects in people. 1998 ipamorelin animal pharmacology study

Human clinical experience includes a randomized postoperative bowel-resection trial: 117 patients enrolled and 114 entered the safety analysis. The authors described intravenous ipamorelin for up to seven days as well tolerated, but the study did not establish chronic subcutaneous safety or compare it with hexarelin. 2014 postoperative ipamorelin trial

FDA separately flags possible aggregation- or impurity-related immunogenicity for ipamorelin acetate and reports serious events, including deaths, in intravenous gastric-motility research. That report does not establish that ipamorelin caused the deaths; the agency also identifies gaps for other injectable routes. Neither the short trial nor the agency summary supports a blanket safe-or-unsafe verdict for every preparation. FDA compound-specific compounding record

Tolerance: Duration and Route Change the Interpretation

In 12 healthy older people, twice-daily subcutaneous hexarelin for 16 weeks produced a smaller but persistent GH response. At the four-week follow-up after treatment, the response was no longer significantly different from baseline. This supports partial, reversible attenuation in that study, not a universal eight-week limit or guaranteed receptor reset. 1998 hexarelin attenuation report

Shorter studies give useful complementary information. Seven older adults retained their GH response during eight days of intranasal hexarelin, and seven older women retained it during 15 days of oral treatment. The oral study also found a small IGF-I increase; neither study reported changes in prolactin or cortisol or reported side effects. These noninjection results do not establish long-term safety or subcutaneous equivalence. 1996 short-term hexarelin study

The reviewed studies do not establish an ideal on/off cycle, show that weekend breaks prevent tolerance, or demonstrate that ipamorelin stays effective indefinitely. A follow-up measurement is not automatically a recommended break between cycles, and an attenuated hormone response is not direct proof of a particular receptor-downregulation mechanism.

Dosing and Preparation: A Study Exposure Is Not a General Protocol

The studies reviewed here do not validate one standard subcutaneous dose, evening schedule, pre-workout timing or injection technique for either peptide. A short infusion experiment cannot supply those answers, and peptide half-life alone does not establish how frequently a treatment should be given.

Combination use also needs its own evidence. A plausible interaction between secretagogue and GHRH signaling does not demonstrate that an ipamorelin/sermorelin stack improves body composition, avoids adverse effects or remains effective for 12-16 weeks. Reports of such use should remain labeled as experience, not a proven protocol.

Preparation and storage depend on the actual product and supporting stability data. Refrigeration is not by itself evidence of sterility, compatibility or a usable shelf life. For a dispensed medicine, resolve unclear dilution, handling or discard instructions with the dispensing pharmacist rather than transferring a generic peptide rule. FDA stability and expiry explanation

The evidence reviewed here does not establish P5P or another hormone-active intervention as a routine way to prevent or manage peptide-related prolactin changes. A suspected adverse effect needs assessment of the actual product, exposure and symptoms, not an automatic addition to a stack.

Choosing by the Outcome, Not a Potency Label

For body composition, direct measurements matter. After 16 weeks of subcutaneous hexarelin, a human study found no significant changes in total body fat, lean body mass or bone mineral density. IGF-I and its binding protein were also unchanged, although one bone-formation marker increased. These findings do not support a predictable 5-15-pound lean-mass gain. 1998 long-term hexarelin study

For ipamorelin, the human infusion and postoperative studies answer different questions from a long-term muscle or fat-loss trial. They should not be turned into a body-composition forecast or proof that ipamorelin is the safer sustained-use option.

Users may report better recovery, sleep or training results. Those experiences can inform questions for research, but concurrent training, nutrition, other treatments and expectations make them an unreliable basis for assigning cause or ranking these two peptides.

Research Evidence and US Product Context

The postoperative ipamorelin trial illustrates why a favorable numerical difference is not automatically a demonstrated benefit. Median time to a tolerated meal was 25.3 hours versus 32.6 hours with placebo, but the difference was not statistically significant (p=0.15); the reported secondary efficacy analyses were also neutral. This was a gastrointestinal endpoint, not a GH or body-composition result. 2014 postoperative ipamorelin trial

The official registry, NCT00672074, identifies the same 117-person intravenous postoperative study and links its publication. The registry and article are two records of one trial, not independent replications. Official NCT00672074 registry

In the US, a research-use label does not place a product outside drug regulation when the evidence establishes intended human use. An FDA warning letter involving a tesamorelin/ipamorelin product makes that distinction explicitly. It is a product-specific enforcement example, not a blanket statement about personal possession or every compounded medicine. 2026 FDA intended-use warning letter

FDA currently lists ipamorelin acetate in category 2 under its 503B interim compounding policy and also identifies a withdrawn nomination. Neither withdrawal nor a compound appearing in a research paper establishes approval. This ipamorelin entry should not be applied to hexarelin as though the two have identical regulatory records. FDA compound-specific compounding record